Amylin, Eli Lilly, and Alkermes have announced long-term, interim results from the Duration-1 study that showed sustained glucose control with weight loss, as well as improvements in systolic
VIVUS has reported the glycemic findings from Equate, a phase-III trial evaluating Qnexain non-diabetic, obese patients. After 28 weeks of treatment, blood sugar levels, as measured by hemoglobin
Amylin has announced that the use of mealtime Symlin (pramlintide acetate) injection has improved glucose control, treatment satisfaction and quality of life for patients with type 2 diabetes.
Eli Lilly has announced positive phase II study results of LY2189265, an investigational glucagon-like peptide 1 (GLP-1) analog. It is to be administered subcutaneously once a week for
The findings of two 52-week studies showed that the investigational ultra rapid acting insulin Afresa Inhalation Powder, combined with basal insulin, is comparable to standard of care therapies
Sanofi-Aventis has come up with the results of a new study – Effects of 1, 2, or 3 prandial injections of insulin glulisine on glycemic control in type
XOMA has announced the new results of Xoma 052, as an entirely new anti-inflammatory approach for the treatment of type 2 diabetes. XOMA 052 is a master signaling
Somaxon, a specialty pharmaceutical company has announced that it has resubmitted New Drug Application (NDA) to FDA for Silenor (doxepin) for the treatment of insomnia. The resubmission includes
Strativa announced that the FDA has accepted its New Drug Application (NDA) for ondansetron orally dissolving film strip (ODFS) for the prevention of nausea and vomiting associated with
Novartis has announced positive results for Tasigna (nilotinib), for treating newly diagnosed chronic myeloid leukemia (CML). The research compared Tasigna against historical Glivec (imatinib) data in the treatment
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.